Fingertips Practice Dashboard (PCN Comparison)
Selected practice
The Woodberry Practice
F85020
PCN: ENFIELD SOUTH WEST PCN
This view compares the selected practice with its PCN average using the same indicator, time period, and visible breakdown where available.
Indicators shown
97
Themes shown
7
Matched PCN rows
97
Average gap
-0.51
Board-ready messages
- Vaccination-related metric appears below PCN.
- A key control metric appears below PCN.
- Smoking prevalence appears above PCN.
Top opportunities vs PCN
Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs)
Other | 2024/25
53.13
-25.68
Patients with severe mental health issues having a comprehensive care plan (denominator incl. PCAs)
Other | 2024/25
72.58
-12.62
For patients with stroke a record exists that an anti-platelet agent or an anti-coagulant is taken (denominator incl. PCAs)
Other | 2024/25
78.87
-10.83
Patients with heart failure due to LVSD treated with beta-blockers (denominator incl. PCAs)
Other | 2024/25
73.81
-10.17
Patients with heart failure who had a review in the last 12 months, including the assessment of functional capacity (denominator incl. PCAs)
Other | 2024/25
80.00
-9.14
Newly diagnosed patients with diabetes referred for an education programme within 9 months (denominator incl. PCAs)
Other | 2024/25
46.34
-8.66
Patients with Asthma: review in the last 12 months (denominator incl. PCAs)
Other | 2024/25
59.26
-8.42
IFCC-HbA1c <= 75 mmol/mol in patients with diabetes and frailty (denominator incl. PCAs)
Outcomes | 2024/25
80.65
-8.19
Top strengths vs PCN
Total number of prescribed antibiotic items per 1000 registered patients by quarter
Prevalence | 2025 Q3
102.94
+29.83
% of patients who felt the waiting time for their appointment was acceptable
Access | 2024
80.42
+18.07
% satisfied with phone access
Access | 2024
66.73
+14.94
Patients with COPD with a MRC dyspnoea score >=3 in the last 12 months, who have had an offer of referral to a pulm. rehab. clinic (denominator incl. PCAs)
Other | 2024/25
46.43
+13.38
% of patients who had a good experience when contacting their GP practice
Access | 2024
77.37
+10.23
Women (25-49 yrs), with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs)
Screening | 2024/25
72.95
+9.53
% of face-to-face appointments
Access | 2024
79.55
+8.98
Last BP reading of patients (80+ yrs, with CHD) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs)
Other | 2024/25
91.55
+7.61
77.37
% of patients who had a good experience when contacting their GP practice
2024 | %
PCN: 67.14
Gap: +10.23
66.73
% satisfied with phone access
2024 | %
PCN: 51.79
Gap: +14.94
80.86
% who have a positive experience of their GP practice
2024 | %
PCN: 74.81
Gap: +6.05
5.44
Asthma: QOF prevalence
2024/25 | %
PCN: 4.58
Gap: +0.86
84.30
Babies who received at least 3 doses of a DTaP vaccine before the age of 8 months
2024/25 | %
PCN: 88.09
Gap: -3.79
79.79
Children who received at least 1 dose of MMR vaccine between the ages of 1 and 1.5 yrs
2024/25 | %
PCN: 77.63
Gap: +2.15
72.59
Children, aged 5, who received a reinforcing dose of DTaP/IPV and at least 2 doses of an MMR vaccine between the ages of 1 and 5 yrs
2024/25 | %
PCN: 73.85
Gap: -1.26
0.94
COPD: QOF prevalence
2024/25 | %
PCN: 0.98
Gap: -0.04
PCN comparison bar chart
Comparison table
| Indicator | Theme | Breakdown | Time period | Practice | PCN | Gap | Unit |
|---|---|---|---|---|---|---|---|
| % active smokers (GPPS) | Other | 16+ yrs | 2024 | 18.61 | 17.84 | +0.78 | % |
| % former smokers (GPPS) | Other | 16+ yrs | 2024 | 19.77 | 22.02 | -2.25 | % |
| % of face-to-face appointments | Access | 16+ yrs | 2024 | 79.55 | 70.57 | +8.98 | % |
| % of patients reporting to suffer from 'long Covid' | Other | 16+ yrs | 2024 | 6.27 | 4.94 | +1.34 | % |
| % of patients who felt the waiting time for their appointment was acceptable | Access | 16+ yrs | 2024 | 80.42 | 62.35 | +18.07 | % |
| % of patients who had a good experience when contacting their GP practice | Access | 16+ yrs | 2024 | 77.37 | 67.14 | +10.23 | % |
| % of patients whose needs were met at their last GP practice appointment | Access | 16+ yrs | 2024 | 91.96 | 89.01 | +2.95 | % |
| % QOF points achieved | Other | Not applicable | Not applicable | 2024/25 | 90.37 | 91.49 | -1.12 | % |
| % reporting a joint problem, such as arthritis | Other | 16+ yrs | 2024 | 11.86 | 15.23 | -3.38 | % |
| % reporting a long-term mental health problem | Other | 16+ yrs | 2024 | 5.05 | 9.98 | -4.93 | % |
| % reporting Alzheimer's disease or dementia | Other | 16+ yrs | 2024 | 0.00 | 0.28 | -0.28 | % |
| % reporting blindness or partial sight | Other | 16+ yrs | 2024 | 0.00 | 0.87 | -0.87 | % |
| % reporting cancer in the last 5 years | Screening | 16+ yrs | 2024 | 1.87 | 1.77 | +0.10 | % |
| % reporting deafness or hearing loss | Other | 16+ yrs | 2024 | 3.57 | 3.27 | +0.30 | % |
| % reporting learning disability | Other | 16+ yrs | 2024 | 6.58 | 2.65 | +3.93 | % |
| % reporting to be unemployed | Other | 16+ yrs | 2024 | 7.61 | 6.46 | +1.15 | % |
| % satisfied with phone access | Access | 16+ yrs | 2024 | 66.73 | 51.79 | +14.94 | % |
| % who have a positive experience of their GP practice | Access | 16+ yrs | 2024 | 80.86 | 74.81 | +6.05 | % |
| % with a long-standing health condition (2024 definition) | Other | 16+ yrs | 2024 | 55.89 | 54.29 | +1.59 | % |
| % with caring responsibility | Other | 16+ yrs | 2024 | 10.24 | 14.38 | -4.15 | % |
| Asthma: QOF prevalence | Prevalence | 6+ yrs | 2024/25 | 5.44 | 4.58 | +0.86 | % |
| Atrial fibrillation: QOF prevalence | Prevalence | All ages | 2024/25 | 2.03 | 1.52 | +0.50 | % |
| Babies who received at least 3 doses of a DTaP vaccine before the age of 8 months | Vaccines | 8 mths | 2024/25 | 84.30 | 88.09 | -3.79 | % |
| Cancer: QOF prevalence | Prevalence | All ages | 2024/25 | 3.60 | 3.15 | +0.45 | % |
| CHD: QOF prevalence | Prevalence | All ages | 2024/25 | 2.35 | 2.38 | -0.04 | % |
| Children who received at least 1 dose of MMR vaccine between the ages of 1 and 1.5 yrs | Vaccines | 18 mths | 2024/25 | 79.79 | 77.63 | +2.15 | % |
| Children, aged 5, who received a reinforcing dose of DTaP/IPV and at least 2 doses of an MMR vaccine between the ages of 1 and 5 yrs | Vaccines | 5 yrs | 2024/25 | 72.59 | 73.85 | -1.26 | % |
| CKD: QOF prevalence | Prevalence | 18+ yrs | 2024/25 | 3.90 | 3.72 | +0.19 | % |
| COPD: QOF prevalence | Prevalence | All ages | 2024/25 | 0.94 | 0.98 | -0.04 | % |
| Dementia care plan has been reviewed in the last 12 months (denominator incl. PCAs) | Other | All ages | 2024/25 | 88.24 | 82.48 | +5.76 | % |
| Dementia: QOF prevalence | Prevalence | All ages | 2024/25 | 0.50 | 0.64 | -0.14 | % |
| Depression: QOF incidence - new diagnosis | Other | 18+ yrs | 2024/25 | 1.36 | 1.35 | +0.01 | % |
| Depression: QOF prevalence | Prevalence | 18+ yrs | 2024/25 | 10.62 | 10.35 | +0.26 | % |
| Deprivation score (IMD 2025) | Inequalities | All ages | 2025 | 15.88 | 21.99 | -6.11 | |
| Diabetes: QOF prevalence | Prevalence | 17+ yrs | 2024/25 | 7.18 | 7.99 | -0.81 | % |
| Epilepsy: QOF prevalence | Prevalence | 18+ yrs | 2024/25 | 0.75 | 0.61 | +0.14 | % |
| For patients with CHD, a record that aspirin, APT or ACT is taken exists (denominator incl. PCAs) | Other | All ages | 2024/25 | 86.50 | 92.96 | -6.46 | % |
| For patients with stroke a record exists that an anti-platelet agent or an anti-coagulant is taken (denominator incl. PCAs) | Other | All ages | 2024/25 | 78.87 | 89.70 | -10.83 | % |
| Heart failure w LVSD: treated with ACE-I or ARB (denominator incl. PCAs) | Other | All ages | 2024/25 | 83.33 | 82.48 | +0.85 | % |
| Heart failure with LVSD: QOF prevalence | Prevalence | All ages | 2024/25 | 0.42 | 0.28 | +0.14 | % |
| Heart Failure: QOF prevalence | Prevalence | All ages | 2024/25 | 0.89 | 0.78 | +0.11 | % |
| Hypertension: QOF prevalence | Prevalence | All ages | 2024/25 | 13.12 | 12.89 | +0.23 | % |
| IFCC-HbA1c <= 58 mmol/mol in patients with diabetes without frailty (denominator incl. PCAs) | Outcomes | 17+ yrs | 2024/25 | 59.96 | 61.52 | -1.55 | % |
| IFCC-HbA1c <= 75 mmol/mol in patients with diabetes and frailty (denominator incl. PCAs) | Outcomes | 17+ yrs | 2024/25 | 80.65 | 88.84 | -8.19 | % |
| Last BP in patients with diabetes is <= 140/80 mmHg (denominator incl. PCAs) | Other | 17+ yrs | 2024/25 | 72.35 | 77.82 | -5.47 | % |
| Last BP reading of patients (80+ yrs, with a history of stroke or TIA) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Other | 80+ yrs | 2024/25 | 82.22 | 84.26 | -2.04 | % |
| Last BP reading of patients (80+ yrs, with CHD) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Other | 80+ yrs | 2024/25 | 91.55 | 83.93 | +7.61 | % |
| Last BP reading of patients (80+ yrs, with hypertension), in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Other | 80+ yrs | 2024/25 | 80.78 | 81.27 | -0.49 | % |
| Last BP reading of patients (<80 yrs, with a history of stroke or TIA) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Other | <80 yrs | 2024/25 | 73.61 | 72.41 | +1.20 | % |
| Last BP reading of patients (<80 yrs, with CHD) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Other | <80 yrs | 2024/25 | 77.11 | 82.78 | -5.67 | % |
| Last BP reading of patients (<80 yrs, with hypertension), in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Other | <80 yrs | 2024/25 | 67.22 | 71.42 | -4.20 | % |
| Learning disability: QOF prevalence | Prevalence | All ages | 2024/25 | 0.48 | 0.52 | -0.04 | % |
| Life expectancy - MSOA based | Other | Female | All ages | 2019 - 23 | 86.19 | 85.79 | +0.40 | Years |
| Mental Health: QOF prevalence | Prevalence | All ages | 2024/25 | 0.95 | 1.25 | -0.30 | % |
| Newly diagnosed patients with depression who had a review 10-56 days after diagnosis (denominator incl. PCAs) | Other | 18+ yrs | 2024/25 | 77.38 | 78.68 | -1.30 | % |
| Newly diagnosed patients with diabetes referred for an education programme within 9 months (denominator incl. PCAs) | Other | 17+ yrs | 2024/25 | 46.34 | 55.00 | -8.66 | % |
| Non-Diabetic Hyperglycaemia (NDH): QOF prevalence | Prevalence | 18+ yrs | 2024/25 | 9.32 | 9.34 | -0.02 | % |
| Obesity: QOF prevalence (new definition) | Prevalence | 18+ yrs | 2024/25 | 11.04 | 11.99 | -0.95 | % |
| Osteoporosis: QOF prevalence | Prevalence | 50+ yrs | 2024/25 | 0.47 | 0.63 | -0.15 | % |
| PAD: QOF prevalence | Prevalence | All ages | 2024/25 | 0.29 | 0.29 | -0.01 | % |
| Palliative/supportive care: QOF prevalence | Prevalence | All ages | 2024/25 | 0.18 | 0.20 | -0.02 | % |
| Patients (aged 45+ yrs), who have a record of blood pressure in the last 5 yrs (denominator incl. PCAs) | Outcomes | 45+ yrs | 2024/25 | 88.60 | 85.59 | +3.01 | % |
| Patients on the Non-Diabetic Hyperglycaemia register who have had an HbA1c or fasting blood glucose test in the preceding 12 months (denominator incl. PCAs) | Prevalence | 18+ yrs | 2024/25 | 87.87 | 85.14 | +2.73 | % |
| Patients with AF who are treated w anti-coag. therapy (CHADS2DS2-VASc >=2) (denominator incl. PCAs) | Other | All ages | 2024/25 | 90.48 | 89.53 | +0.95 | % |
| Patients with Asthma (6-19 yrs): Second-hand smoking status recorded in the last 12 months (denominator incl. PCAs) | Other | 6-19 yrs | 2024/25 | 53.13 | 78.81 | -25.68 | % |
| Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Other | 6+ yrs | 2024/25 | 59.26 | 67.68 | -8.42 | % |
| Patients with cancer reviewed within 12 months of diagnosis (denominator incl. PCAs) | Screening | All ages | 2024/25 | 100.00 | 98.66 | +1.34 | % |
| Patients with cancer who had an opportunity for a discussion within 3 months of diagnosis (denominator incl. PCAs) | Screening | All ages | 2024/25 | 94.74 | 94.40 | +0.34 | % |
| Patients with COPD who had a review in the last 12 months (denominator incl. PCAs) | Other | All ages | 2024/25 | 70.53 | 75.77 | -5.24 | % |
| Patients with COPD with a MRC dyspnoea score >=3 in the last 12 months, who have had an offer of referral to a pulm. rehab. clinic (denominator incl. PCAs) | Other | All ages | 2024/25 | 46.43 | 33.05 | +13.38 | % |
| Patients with diabetes (40+ yrs, no history of CVD) treated with a statin (denominator incl. PCAs) | Other | 40+ yrs | 2024/25 | 73.03 | 77.61 | -4.58 | % |
| Patients with diabetes and a history of CVD (excl. haem. stroke) treated with a statin (denominator incl. PCAs) | Other | 17+ yrs | 2024/25 | 84.32 | 89.44 | -5.11 | % |
| Patients with diabetes and proteinuria/micro-albuminuria treated with ACE inhibitors (denominator incl. PCAs) | Other | 17+ yrs | 2024/25 | 81.58 | 77.59 | +3.99 | % |
| Patients with diabetes who had a foot examination and risk classification (denominator incl. PCAs) | Other | 17+ yrs | 2024/25 | 72.96 | 74.35 | -1.39 | % |
| Patients with heart failure due to LVSD treated with beta-blockers (denominator incl. PCAs) | Other | All ages | 2024/25 | 73.81 | 83.98 | -10.17 | % |
| Patients with heart failure who had a review in the last 12 months, including the assessment of functional capacity (denominator incl. PCAs) | Other | All ages | 2024/25 | 80.00 | 89.14 | -9.14 | % |
| Patients with psychosis who have a current record of a lipid profile | Other | All ages | 2024/25 | 83.87 | 88.06 | -4.19 | % |
| Patients with psychosis who have a current record of alcohol consumption | Other | All ages | 2024/25 | 83.87 | 90.65 | -6.78 | % |
| Patients with psychosis who have a current record of blood glucose or HbA1c | Outcomes | All ages | 2024/25 | 82.14 | 86.32 | -4.18 | % |
| Patients with severe mental health issues having a comprehensive care plan (denominator incl. PCAs) | Other | All ages | 2024/25 | 72.58 | 85.20 | -12.62 | % |
| Patients' heart failure diagnosis confirmed by an ECG or specialist assessment (denominator incl. PCAs) | Other | All ages | 2024/25 | 88.89 | 90.41 | -1.53 | % |
| Patients, aged 80, who received a shingles vaccine between the ages of 70 and 79 yrs | Vaccines | 80 yrs | 2024/25 | 76.56 | 79.76 | -3.20 | % |
| Percentage of broad-spectrum prescribed antibiotic items (cephalosporin, quinolone and co-amoxiclav class) by quarter | Other | All ages | 2025 Q3 | 14.52 | 10.56 | +3.96 | % |
| Proportion of GP registered populations by age group | Prevalence | 15+ yrs | 2025 | 83.16 | 83.16 | 0.00 | % |
| Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | Prevalence | All ages | 2024/25 | 85.48 | 91.34 | -5.85 | % |
| Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | Prevalence | All ages | 2024/25 | 83.87 | 91.38 | -7.50 | % |
| Record of offer of support and treatment in the last 24 months for smokers aged 15+ yrs (denominator incl. PCAs) | Other | 15+ yrs | 2024/25 | 90.46 | 92.83 | -2.36 | % |
| Rheumatoid Arthritis: QOF prevalence | Prevalence | 16+ yrs | 2024/25 | 0.71 | 0.55 | +0.16 | % |
| Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | Other | All ages | 2024/25 | 97.76 | 97.71 | +0.05 | % |
| Smoking status of patients with certain conditions recorded in the last 12 months (denominator incl. PCAs) | Other | All ages | 2024/25 | 87.84 | 93.20 | -5.36 | % |
| Smoking: QOF prevalence | Prevalence | 15+ yrs | 2024/25 | 12.60 | 14.96 | -2.36 | % |
| Stroke risk of patients with AF assessed with CHA2DS2-VASc (denominator incl. PCAs) | Other | All ages | 2024/25 | 93.78 | 98.21 | -4.43 | % |
| Stroke: QOF prevalence | Prevalence | All ages | 2024/25 | 1.16 | 1.26 | -0.11 | % |
| Total number of prescribed antibiotic items per 1000 registered patients by quarter | Prevalence | All ages | 2025 Q3 | 102.94 | 73.11 | +29.83 | per 1,000 |
| Total number of prescribed antibiotic items per STAR-PU by quarter - GP | Other | All ages | 2025 Q3 | 0.19 | 0.14 | +0.05 | Number of items prescribed |
| Women (25-49 yrs), with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Screening | Female | 25-49 yrs | 2024/25 | 72.95 | 63.42 | +9.53 | % |
| Women (50-64 yrs), with a record of cervical screening in the last 5.5 yrs (denominator incl. PCAs) | Screening | Female | 50-64 yrs | 2024/25 | 79.07 | 73.77 | +5.30 | % |